Wagner, Andrew J.

Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine

Musculoskeletal synovial abnormalities and treatmentsRheumatoid Arthritis Research and Therapies

Cited by 582

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry

Cell death mechanisms and regulationHeterocyclic Compound Synthesis and Bioactivity

Cited by 252

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment

Cited by 165

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 127

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 120

Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo

Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 114

Aberrant AKT activation drives well-differentiated liposarcoma

Gutierrez, A., Snyder, E. L., Marino-Enriquez, A., Zhang, Y.-X., Sioletic, S., Kozakewich, E., Grebliunaite, R., Ou, W.-B., Sicinska, E., Raut, C. P., et al. (2011) · Proceedings of the National Academy of Sciences

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 58

Implementation to optimization: a tailored, data-driven approach to improve provider efficiency and confidence in use of the electronic medical record

Kadish, S. S., Mayer, E. L., Jackman, D. M., Pomerantz, M., Brady, L., Dimitriadis, A., Cleveland, J. L. F., & Wagner, A. J. (2018) · Journal of Oncology Practice

Electronic Health Records SystemsNursing Diagnosis and Documentation

Cited by 27

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency

Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S. (2026) · JCO Precision Oncology

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 0